Latest Industry Insights
Revolutionizing the Science of Nerve Repair and Regeneration
To learn more about the causes and consequences of peripheral nerve damage and some of the solutions available to patients, Technology Networks spoke with Karen Zaderej, chief executive officer of Axogen.
The Value of Investing in Sex- and Gender-Based Alzheimer’s Disease Research
Women’s Health Access Matters recently released The WHAM Report, outlining new research conducted by the RAND Corporation to study the impact of accelerating sex- and gender-based AD, heart and autoimmune research on women, their families and the economy. To learn more about the report, the recently released AD findings and their significance, we spoke to Carolee Lee, founder and CEO of WHAM.
Cancer Research: Potential Key To Unlocking Alzheimer’s Disease Therapies
In the search to discover new therapeutic approaches for AD, scientists are finding new inspiration where others may have never thought to look: cancer research trends.
A “Living Pharmacy” That Can Shift the Body’s Circadian Clock
Many of us are familiar with the undesirable physical and mental effects of a disrupted sleep/wake cycle caused by traveling across multiple time zones or working irregular hours. A collaborative project designed to address these issues is working to develop a “living pharmacy” – a personalized, wireless and fully implantable device that can control the body’s circadian clock.
Could Fly Agaric Mushroom Compound Muscimol Be a Successful Psychedelic?
Technology Networks recently spoke with Jeff Stevens, Psyched Wellness’s CEO, to learn more about muscimol, its therapeutic potential and how it compares to other psychedelics such as psilocybin.
Interview: Behind the E-mmunotherapy Earbud That Could Treat Arthritis
Non-invasive stimulation company Nēsos recently announced that its “e-mmunotherapy” earbud has been granted breakthrough device designation by the US Food and Drug Administration (FDA) for patients with rheumatoid arthritis (RA). We spoke to Konstantinos Alataris, president and CEO of Nēsos, to find out more about the company's device and its potential applications.
Non-Hallucinogenic Psychedelic Analogs Could Be Game Changers for Neuropsychiatry
In this interview, David E. Olson discusses the potential commercial, clinical and scientific implications of non-hallucinogenic psychedelic compounds.
How CRISPR-Based Gene Engineering Is Helping To Accelerate Alzheimer’s Disease Research
To learn about some of the main challenges associated with generating a large library of edited iPSCs and the role that Synthego is playing in the iNDI project, we spoke to Synthego’s CSO, Dr Robert Dean.
The Ins and Outs of Psychedelic-Assisted Psychotherapy
To learn more about psychedelic-assisted psychotherapy, the advantages it offers and some of the conditions it could help to treat, Technology Networks spoke with Dr Reid Robison, chief medical officer of Novamind, a mental health company specialized in psychedelic medicine.
How Can Informatics Make the Post-COVID Workplace Safe and Secure?
As COVID-19 vaccination programs kick into gear, private and public workplaces are weighing up the risks and benefits of asking employees to return to the office. Affinity Empowering Inc, who offer workplace eHealth compliance services, have rolled out an end-to-end COVID-19 testing program to assist employers in their return to work protocols. We spoke to Affinity CEO Scott Storrer to find out more.